For example, two PPARγ agonists, troglitazone and rosigliatzone, have been reported to promote gastrointestinal tumorigenesis in C57BL/6J APCMin/+ mice [11, 79], raising the serious concerns about the possibility that individuals who are on TZDs for T2DM might be at risk for colon cancer. The gene discussed is PPARG; the disease is malignant colon neoplasm.